HS 300190 Other

```html

What products does HS 300190 cover?

This subheading covers "Other" products within Heading 3001, which pertains to glands and other organs for organotherapy, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organotherapy; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included. HS 300190 specifically includes substances derived from glands or organs that are not covered by more specific subheadings, such as dried glands themselves or heparin. The World Customs Organization (WCO) Explanatory Notes clarify that this category is for residual items within the heading, provided they meet the criteria for organotherapy preparations. For example, certain glandular extracts not specifically enumerated elsewhere would fall here.

What falls outside HS 300190?

The following products are excluded from HS 300190: whole or parts of glands and other organs for organotherapy (covered by 3001.10 and 3001.20), heparin and its salts (covered by 3001.30), and any substances intended for diagnostic purposes rather than therapeutic or prophylactic use. Additionally, finished pharmaceutical products (Chapter 30, heading 3002 to 3006), vaccines, blood fractions, and animal feed supplements are classified elsewhere. For instance, a powdered liver extract intended as a dietary supplement would not fall under 300190 but likely under Chapter 21 or 29 depending on its processing.

What are common classification mistakes for HS 300190?

A common error is misclassifying finished pharmaceutical preparations or dietary supplements as "other" organotherapy products. This often arises from a misunderstanding of the scope of Heading 3001 and the General Rules for the Interpretation of the Harmonized System (GRI), particularly GRI 1, which states that classification shall be determined according to the terms of the headings and any relative section or chapter notes. For example, a highly processed glandular extract with added excipients, intended for direct human consumption as a supplement, might be incorrectly entered under 300190 instead of a more appropriate heading for finished pharmaceutical products or food supplements.

How should importers classify products under HS 300190?

The correct procedure for classifying products under HS 300190 involves a thorough examination of the product's composition, intended use, and processing. Importers must first determine if the product is a gland or organ for organotherapy, an extract thereof, heparin, or another human or animal substance prepared for therapeutic or prophylactic uses. If it fits within the broad scope of Heading 3001 but is not specifically covered by other subheadings (3001.10 to 3001.30), then 300190 is the appropriate classification. Consulting the WCO Explanatory Notes and national tariff schedules, such as the USITC Harmonized Tariff Schedule (HTS) or the EU's TARIC database, is crucial for accurate determination.

How is the duty calculated for products under HS 300190?

A shipment of 10 kilograms of dried, powdered adrenal gland extract, declared at a customs value of $5,000 USD, would attract a US Most Favored Nation (MFN) duty of $500.00. This is calculated using the MFN rate of 10% ad valorem, as published in the USITC Harmonized Tariff Schedule for HS code 300190. The calculation is: 10% × $5,000 USD = $500.00. It is essential to verify the specific duty rate applicable to the country of origin and the importing jurisdiction, as preferential rates may apply.

Which trade agreements reduce duties for HS 300190?

Several free trade agreements may reduce the applicable duty rate for HS 300190, including the United States-Mexico-Canada Agreement (USMCA) and the Generalized System of Preferences (GSP) for certain developing countries. Under USMCA, originating products from Canada or Mexico may be eligible for duty-free entry. For GSP beneficiaries, the preferential rate is often Free, provided the origin requirements are met. Documentation typically includes a self-certified origin statement for USMCA, or a GSP Form A for GSP eligible countries, to claim these preferences in the respective importing countries.

```